US3966962A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Triacetin solutions of PGE-type compounds
Assignee: Pharmacia and Upjohn Co
•
Filing: 1975-03-27
•
Granted: 1976-06-29
•
Expires: 1995-03-27
Abstract
Abstract A stable dosage form of PGE-type compounds is obtained by dissolving these compounds in triacetin.
Inventors
- 👤 Samuel H. Yalkowsky
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 19:15
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/557; A61K47/00; A61K47/06; A61K47/08; A61K47/14; A61P; A61P43/00
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
19 words
A stable dosage form of a prostaglandin-like compound of the PGE-type comprising a solution of said compound in triacetin.
Claim 2
Dependent Claim
19 words
A stable dosage form of a prostaglandin-like compound of the PGE-type comprising a solution of said compound in triacetin.
Claim 3
Dependent Claim
26 words
A stable dosage form according to claim 1 wherein said solution contains said compound in a concentration range 0.1 to 10 mg. per ml. of triacetin.
Claim 4
Dependent Claim
22 words
A stable dosage form according to claim 1 wherein said solution is contained in a capsule of a pharmaceutically acceptable water-dispersable material.
Claim 5
Dependent Claim
20 words
A stable dosage form according to claim 3 wherein said material contains gelatin and the capsule is soft and elastic.
Claim 6
Dependent Claim
41 words
A stable dosage form according to claim 1 wherein said compound is PGE 2 , PGE 2 methyl ester, 16,16-dimethyl-PGE 2 , 16,16-dimethyl-PGE 2 methyl ester, 15-methyl-PGE 2 , 15-methyl-PGE 2 methyl ester, 15(R)-15-methyl-PGE 2 , or 15(R)-15-methyl-PGE 2 methyl ester.
Claim 7
Dependent Claim
37 words
A stable dosage form according to claim 5 wherein the triacetin solution is contained in a soft elastic gelatin capsule, and said compound is present in a concentration range 0.1 to 10 mg. per ml. of triacetin.
Claim 8
Dependent Claim
36 words
A stable dosage form according to claim 4 wherein the compound is 16,16-dimethyl-PGE 2 or 16,16-dimethyl-PGE 2 methyl ester, and said compound is present in a concentration range 0.5 to 5 mg. per ml. of triacetin.
Claim 9
Dependent Claim
36 words
A stable dosage form according to claim 4 wherein the compound is 15-methyl-PGE 2 or 15-methyl-PGE 2 methyl ester, and said compound is present in a concentration range 0.5 to 5 mg. per ml. of triacetin.
Claim 10
Dependent Claim
36 words
A stable dosage form according to claim 4 wherein the compound is 15(R)-15-methyl-PGE 2 or 15(R)-15-methyl-PGE 2 methyl ester, and said compound is present in a concentration range 0.5 to 5 mg. per ml. of triacetin.
References Cited (Backward Citations)
US3829579A
Cited
US3833725A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-06-29 | 1979-12-29 | 1980-06-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-06-29 | 1983-12-29 | 1984-06-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-06-29 | 1987-12-29 | 1988-06-29 | $7700.00 | Window Closed / Lapsed |